NFKB1 and CD4+/CD56+ hematodermic neoplasm: Subsequently, Philippe et al[77] further demonstrated that bortezomib effectively inhibited the phosphorylation of the NF-κB subunit, RelA in BPDCN cells both in vivo and in vitro, thereby significantly improving the survival rate of mice.